These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 19157633

  • 1. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 2. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 3. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 4. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 5. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF.
    Genet Mol Res; 2014 Mar 31; 13(3):7617-25. PubMed ID: 24737519
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL, Sun XC, Chen BA, Sun N, Cheng HY, Li F, Zhang HM, Feng JF, Qin SK, Cheng L, Lu ZH.
    Chin Med J (Engl); 2010 Dec 31; 123(23):3427-32. PubMed ID: 22166526
    [Abstract] [Full Text] [Related]

  • 9. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 31; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 10. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C, Duan Z, Li P, Xu Q, Yuan Y.
    Anticancer Drugs; 2013 Mar 31; 24(3):300-5. PubMed ID: 23211354
    [Abstract] [Full Text] [Related]

  • 11. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X.
    Int J Hyg Environ Health; 2010 Mar 31; 213(2):140-5. PubMed ID: 20189873
    [Abstract] [Full Text] [Related]

  • 12. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, Mady HH, Melhem MF, Keohavong P.
    Carcinogenesis; 2003 Oct 31; 24(10):1671-6. PubMed ID: 12844488
    [Abstract] [Full Text] [Related]

  • 13. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.
    Clin Lung Cancer; 2009 Mar 31; 10(2):118-23. PubMed ID: 19362955
    [Abstract] [Full Text] [Related]

  • 14. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Xu BH, Lin DX.
    Zhonghua Yi Xue Za Zhi; 2005 Apr 13; 85(14):972-5. PubMed ID: 16061005
    [Abstract] [Full Text] [Related]

  • 15. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 16. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
    Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, Lee HP.
    Gynecol Oncol; 2006 Dec 01; 103(3):1031-7. PubMed ID: 16875718
    [Abstract] [Full Text] [Related]

  • 17. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.
    Lung Cancer; 2012 Sep 10; 77(3):578-84. PubMed ID: 22608006
    [Abstract] [Full Text] [Related]

  • 19. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer.
    Jeon HS, Kim KM, Park SH, Lee SY, Choi JE, Lee GY, Kam S, Park RW, Kim IS, Kim CH, Jung TH, Park JY.
    Carcinogenesis; 2003 Oct 10; 24(10):1677-81. PubMed ID: 12869423
    [Abstract] [Full Text] [Related]

  • 20. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug 10; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.